News | Heart Valve Technology | August 31, 2015

Mitralign Receives FDA Approval for Percutaneous Tricuspid Repair Early Feasibility Study

The Mitralign Percutaneous Tricuspid Valve Annuloplasty System to be available for clinical study in the United States

Mitralign, Percutaneous Tricuspid Valve Annuloplasty System

Mitralign's Percutaneous Tricuspid Valve Annuloplasty System uses catheter delivered pledgeted sutures that can be cinched together to change the valve annulus geometry to help eliminate valvular regurgitation. 

August 31, 2015 — Mitralign Inc. said the U.S. Food and Drug Administration (FDA) granted an investigational device exemption (IDE) so the company can conduct an early feasibility study to examine its Percutaneous Tricuspid Valve Annuloplasty System (PTVAS). The SCOUT Study will take place in select centers in the United States.

“Percutaneous repair of the tricuspid valve represents one of the largest remaining unmet needs in the structural heart space,” said Rick Geoffrion, chief executive officer of Mitralign. “We mimic a known surgical procedure but do not require open heart surgery, providing a potential treatment option for a large number of patients that are too sick for surgical intervention. This approval from the FDA demonstrates their continued commitment to encouraging medical device innovation to address clinical needs and improve patient care.”

“Even though the first group of patients treated were very sick, compassionate use candidates in Europe, the system has shown an excellent safety profile along with tremendous improvements in significant clinical measures,“ commented Rebecca Hahn, M.D., director of interventional echocardiography, Columbia University Medical Center / New York Medical Center / New York Presbyterian Hospital and principal investigator for the SCOUT study. “This patient population has very limited options, and the possibility of performing a transcatheter repair is very exciting. This innovation has significant potential to be a first line therapy.”

Mitralign is the first company to provide interventional cardiologists with the tools to perform minimally invasive, percutaneous procedures for both functional mitral regurgitation and tricuspid regurgitation with the Mitralign Percutaneous Mitral Repair System expected to receive CE mark approval for treatment of functional mitral regurgitation (FMR) in 2015. Both systems utilize the same innovative platform. The Percutaneous Tricuspid Valve Annuloplasty System and Mitralign Percutaneous Mitral Repair System are under clinical investigation and not available for sale or distribution.

Tricuspid regurgitation (TR) Tricuspid regurgitation occurs when the tricuspid valve fails to open and close properly, causing blood to flow backwards into the right atrium. If left untreated, TR can lead to heart enlargement and heart failure.  In the U.S. alone, there are an estimated 1.6 million patients suffering from TR.[1] It is estimated that 50 percent of patients with mitral regurgitation have moderate to severe tricuspid regurgitation.[2] TR is currently undertreated by surgery. In the United States, surgeons treat only 5,500[3] patients per year, most of them in conjunction with left heart surgeries. When treating the valves, surgeons choose repair 90 percent of the time versus replacement (10 percent).[3]

For more information: www.mitralign.com

References:
1. Stuge O., Liddicoat J., et al. JTCS 2006;132:1258-61
2. Argarwal et al. Circ Cardiovasc Interv 2009;2:565-573
3. RogersJH.Circulation2009:119: 2718-25    

 

Related Content

A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation. Abbott Mitraclip device.

A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation.

News | Structural Heart | May 11, 2018
May 11, 2018 — The post-approval study evaluating the safety and efficacy of MitraClip in a real-world, commercial se
SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart | January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
Videos | Structural Heart | November 09, 2016
Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance
aortic dissection, family history, same age, clinical study, John A. Elefteriades, Annals of Thoracic Surgery
News | Structural Heart | August 25, 2016
People with a family member who had an aortic dissection — a spontaneous tear in one of the body’s main arteries —...
Videos | Structural Heart | June 30, 2016
Interview with Stephen Little, M.D., medical director of the Valve Clinic at the Houston Methodist DeBakey Heart and
AATS 2016, tricuspid regurgitation, post mitral valve repair, Tirone E. David, atrial fibrillation
News | Structural Heart | May 16, 2016
At the 96th American Association for Thoracic Surgery (AATS) Annual Meeting, investigators presented the results of a...
CABG, mitral valve repair, ischemic mitral regurgitation, IMR, study, ACC 2016
News | Structural Heart | April 11, 2016
Just-released two-year follow-up data comparing coronary-artery bypass grafting (CABG) with combined CABG and mitral-...
V-Wave Interarterial Shunt, first human results, The Lancet, heart failure, HF
News | Structural Heart | March 28, 2016
V-Wave Ltd, maker of an investigational interatrial shunt device for patients with advanced heart failure (HF),...
News | Structural Heart | March 02, 2016
Edwards Lifesciences Corp. announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards...
AtriCure, AtriClip, ATLAS study, first patient enrolled, POAF, post-operative atrial fibrillation
News | Structural Heart | February 18, 2016
AtriCure Inc. announced that the first patient was enrolled and treated at PinnacleHealth Hospitals in Harrisburg, Pa...
Overlay Init